Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
about
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary diseaseLong-acting beta2-agonists for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseExtrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary diseaseA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseasePrevention of COPD exacerbations: medications and other controversiesA score to predict short-term risk of COPD exacerbations (SCOPEX).Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia.The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trialsRisk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and updateElevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy.Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses.Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary diseaseRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β₂ -agonists in obstructive lung diseases: a population-based, observational studyOvertreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study.Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Targeting IL-1β and IL-17A driven inflammation during influenza-induced exacerbations of chronic lung inflammationManagement of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians.Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trialEffects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPDEfficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary diseaseMortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled TrialAclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)ADRB2 polymorphisms and budesonide/formoterol responses in COPD.Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Cohort StudyThe EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.The role of bronchodilator treatment in the prevention of exacerbations of COPD.Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.Optimizing safety of COPD treatments: role of the nurse practitioner.Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis.The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.
P2860
Q22305858-C4F44B1C-790C-4A3A-B5BC-0513E93C8C09Q24197467-559D8915-37ED-4F95-A1CF-B1DDD1941D23Q24197853-485043E8-FA4F-494F-962A-A12256E8E890Q24197989-F6665C51-A4DC-4612-818B-EFF2D137B74FQ24199130-A5755809-4A10-4E89-A64A-F45470536C1CQ24200446-F76CB42E-03EA-4FC7-801C-0EBE247F1409Q24202510-47231C57-81E9-42BD-8FDF-413366699BE1Q26745663-3864F01B-4299-4A85-A218-67207C967599Q26801661-BD92E7DD-372E-4372-A16B-F6AC027821DBQ28596774-5ABAF0EC-B52F-432A-B1D0-CEC88C7FC2AAQ30619543-8BA73F22-B8F4-4C0C-8839-F0E805D50B06Q33709357-929811D0-EF22-494A-A3C7-1C2D9A2BC9C6Q33713847-56B571E5-A20C-4CD9-92C6-D4D9BC01E015Q34015461-315445DF-67EF-40E5-BC88-782D60916395Q34036358-FF63B0F3-CE38-4F9F-A716-31C70E152F52Q34172077-C96954AC-E011-4C18-9415-2C5B9F8BF7FEQ34198955-E09762BB-91AB-4F15-9B69-42EEC8CF5231Q34423324-3BC79599-792F-4BAE-8516-8948B10141D6Q34554816-4B6ECFA7-0A37-4528-8708-D07E3663FB60Q34957303-1F5D5FDE-FDF2-4180-A182-0BF7959C3D30Q35022943-51C71487-3F2A-4EE1-AD31-5B3E055A502FQ35032254-E015AF07-A249-44FF-8E67-7E604F9143DFQ35140742-C42FA8B8-BB5D-49B5-8050-CCD51D209ABAQ35185316-627F06CE-71D9-444E-A5C0-2E7BB3189AF2Q35225129-197D9DC5-7637-41D9-9999-695C2250C646Q35747036-C7E6D743-68A7-449C-93C3-B8D8C453422BQ35747040-9F08D8F2-CCFC-4ECD-B004-45ED01BE0458Q35747045-152BA8A9-41A2-42ED-A702-BE0A9C6B462CQ35751737-91CD7D66-5F5C-4D20-ACC1-E4EB0E081926Q35838660-1DAC0D72-21DF-40CA-A2E5-0BDE4CC0B125Q35867300-A9FB6465-4019-4030-A8CD-DBEA9ED0DD3EQ35937943-E5F1CBBA-6DF2-4BC4-B3FD-4C76F4EAADA3Q36182193-804A0639-C908-4991-8CBD-9C3152AA5FAAQ36206896-676FE990-A07A-4012-8750-AF060E0BC536Q36288980-3F8AD9F9-6A19-43A3-9FCC-8A61B6827395Q36438669-98D58682-E6D0-471D-86AE-86DB61DCBBC6Q36636050-71EB2329-D2AF-4CDC-A5DD-60DC0CA33E3AQ36642198-F78EC296-A0E8-4F8D-95D0-581F7D730BB3Q37109222-6BA24BF9-6228-47E5-AE36-83A7B63D0A83Q37128138-9FFFBE07-B506-44F8-AA9F-0F1A1F0E3F54
P2860
Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Efficacy and tolerability of b ...... zed controlled clinical trial.
@ast
Efficacy and tolerability of b ...... zed controlled clinical trial.
@en
type
label
Efficacy and tolerability of b ...... zed controlled clinical trial.
@ast
Efficacy and tolerability of b ...... zed controlled clinical trial.
@en
prefLabel
Efficacy and tolerability of b ...... zed controlled clinical trial.
@ast
Efficacy and tolerability of b ...... zed controlled clinical trial.
@en
P2093
P2860
P1433
P1476
Efficacy and tolerability of b ...... zed controlled clinical trial.
@en
P2093
Donald P Tashkin
Jennifer McElhattan
Mitchell Goldman
Stephen I Rennard
Sulabha Ramachandran
Ubaldo J Martin
P2860
P304
P356
10.2165/00003495-200969050-00004
P577
2009-01-01T00:00:00Z
P5875
P6179
1014199671